CardioDynamics Announces Fourth Quarter and Fiscal Year-End 2003 Conference Call and Webcast.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--Jan. 15, 2004 CardioDynamics (Nasdaq:CDIC CDIC Chronic Diseases In Canada (journal) CDIC Canadian Deposit Insurance Corporation CDIC Carbon Dioxide Information Center CDIC Center for Data Intensive Computing (BNL) ), the innovator and leader of Impedance Cardiography Impedance cardiography is a hemorheology technique of using sensors to detect the properties of the blood flow in the Thorax. Introduction Impedance cardiography (ICG), also referred to as thoracic electrical bioimpedance (TEB) and electrical impedance plethysmography (ICG ICG indocyanine green. ) technology, has scheduled a conference call and Internet webcast for Wednesday, January 21, 2004 at 4:30 p.m. EST to discuss the Company's financial results for the fiscal fourth quarter and fiscal year 2003. The call will be hosted by CardioDynamics' Chief Executive Officer, Michael K. Perry and Chief Financial Officer, Steve P. Loomis. A press release announcing fourth quarter and fiscal 2003 results will be released after close of market on January 21, 2004. Conference Call and Webcast Information: To access the conference call, dial 800-346-7359 (Code 7784). International participants can call 973-528-0008 (Code 7784). A replay of the call will be available for one month following the call at 800-332-6854 (Code 7784). The international replay number is 973-528-0005 (Code 7784). The Internet webcast can be accessed at http://www.irconnect.com/primecast/03/q4/cdic_4q2003.html. Any questions regarding this notice should be directed to Bonnie bon·ny also bon·nie adj. bon·ni·er, bon·ni·est Scots 1. Physically attractive or appealing; pretty. 2. Excellent. Ortega at 800-778-4825, ext. 1005, or via e-mail, bortega@cdic.com. About CardioDynamics: CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator and leader of breakthrough medical technology called Impedance Cardiography (ICG). The Company's BioZ(R) Systems are being used by leading physicians around the world to help battle the number one killer of men and women -- cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . Partners include GE Medical Systems Information Technologies and Philips Medical Systems. The worldwide market potential for BioZ products is estimated to be $5 billion and an additional $800 million in recurring annual revenue for sensors. For additional information or to request an investor package, please refer to the company's Web site at www.cdic.com. Forward-Looking (Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. ) Statement: Except for the historical and factual information contained herein, this press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. , such as market size, potential, growth and penetration rates, the accuracy of which is necessarily subject to uncertainties and risks including the Company's sole dependence on the BioZ product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2002 Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. . The Company does not undertake to update the disclosures contained in this press release. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion